Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Completed 3Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 3Observational 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Plasma cell 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 24Recurrence 5Neoplasms 2Leukemia 2Carcinoma, Non-Small-Cell Lung 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Multiple Myeloma 1Leukemia, Myeloid 1Hematologic Neoplasms 1Advanced Solid Tumors 1

Interventions

Dexamethasone 64Cyclophosphamide 35pomalidomide 34Lenalidomide 34Rituximab 31Bortezomib 30venetoclax 28fludarabine 27Gemcitabine 21carfilzomib 20Paclitaxel 19pembrolizumab 17daratumumab 17Cisplatin 16Carboplatin 15Calcium Dobesilate 14Azacitidine 14ibrutinib 12Docetaxel 12Cytarabine 12obinutuzumab 11Nivolumab 11durvalumab 10Injections 10Doxorubicin 10Bevacizumab 10selinexor 9cemiplimab 9blinatumomab 9Cetuximab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Recurrence × gilteritinib × Clear all
NCT04988555 2026-03-24

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Sumitomo Pharma America, Inc.

Phase 1/2 Recruiting
606 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Multiple Myeloma, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06734585 2025-09-12

Using Gilteritinib to Keep People With Acute Myeloid Leukemia Cancer-free After a Stem Cell Transplant

Astellas Pharma Inc

Completed
114 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT04691648 2025-05-31

A Study to Assess the Safety of Xospata in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-Like Tyrosine Kinase 3 (FLT3) Mutation

Astellas Pharma Inc

Completed
33 enrolled
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT05279859 2022-06-15

HERKULES-4

Erasca, Inc.

Phase 1/2 Withdrawn
Other hematologic neoplasm

Recurrence, Leukemia, Myeloid, Acute

NCT03625505 2021-09-14

A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia

AbbVie

Phase 1 Completed
61 enrolled
Other hematologic neoplasm

Neoplasms, Recurrence, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡